May 9th 2024
As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
After Announcing Global Biosimilar Initiative, Sandoz Sees EU Biosimilar Application Acceptance
June 20th 2022Not long after the company announced its new global initiative to promote access and increase adoption of biosimilars, Sandoz’ biologics license application for its high-concentration adalimumab biosimilar was accepted by the European Union’s regulatory agency for review.
Eye on Pharma: New Indication for Riabni, Organon and Henlius Partner on 2 Biosimilar Candidates
June 14th 2022The FDA granted a new indication for rheumatoid arthritis for Riabni, a rituximab biosimilar, and Organon and Shanghai Henlius Biotech entered into a licensing agreement for 2 oncology biosimilar candidates.
Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions
May 4th 2022The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.
The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei
May 3rd 2022The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.
Dr Sarfaraz K. Niazi Claims Biosimilar Growth Signals Need for Greater Testing, Policy Reform
April 28th 2022Now that the United States’ acceptance of biosimilars matches that in the European Union, developers should be encouraging changes to testing regulations to increase biosimilar accessibility, according to Sarfaraz K. Niazi, PhD, in his recent perspective paper.
Opinion: Biosimilar Adoption Will Help Achieve a Bipartisan Goal
April 25th 2022Biosimilars provide significant savings and encourages competition in the biopharmaceutical marketplace but the United States needs to do more to empower uptake and address adoption barriers, according to Robert Popovian PharmD, MS.
Prioritizing Reference Products Over Biosimilars Led to Millions in Missed Savings for Part D
April 20th 2022Medicare Part D plans missed out on between $84 million and $143 million in savings by not prioritizing the use of biosimilars over reference products, according to a report from the HHS Office of Inspector General.
Review of Totality of Evidence for Infliximab Biosimilar ABP 710
March 30th 2022An article reviewed the totality of evidence leading to the approval of Amgen’s infliximab biosimilar ABP 710 (Avsola), which is currently approved in the US and Canada for all the indications of the originator (Remicade).
Jeffery Casberg Previews His Presentations at AMCP 2022
March 27th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.
China’s NMPA Grants Greater Access to Rheumatology Biosimilars
March 21st 2022Since the start of 2022, China’s National Medicinal Products Administration (NMPA) has made strides to increase access to biosimilar products for various rheumatic conditions, including 3 biosimilar approvals and 1 biosimilar receiving an expanded indication.